Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals today reported financial results for the fourth quarter and full year ended December 31, 2023.

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement


Crinetics announces that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors.

Crinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024


Crinetics will host a conference call and webcast on February 28th at 4:30 p.m. ET to discuss fourth quarter and full year 2023 financial results and provide a business update.

Crinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new non-executive employees

Crinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new non-executive employees